Tenaya Therapeutics (TNYA) will announce initial Cohort 1 data from the MyPEAK-1 Phase 1b/2 clinical trial of TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy on Tuesday, December 17.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNYA:
- Tenaya Therapeutics doses first patient with TN-401 gene therapy
- Tenaya Therapeutics Reports Q3 2024 Progress and Financial Results
- Tenaya Therapeutics reports inducement grants under Nasdaq listing rule
- Tenaya Therapeutics price target raised to $18 from $16 at Canaccord
- Tenaya Therapeutics reports Q3 EPS (30c), consensus (37c)